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ABSTRACT 
Background: Hepatitis C  virus  infection  has  been  associated  with  various  extra-hepatic manifestations, and diabetes mellitus  is  one of  these.  Chronic hepatitis C virus 
infection and type 2 diabetes mellitus cause long-term complications in affected patients. Moreover, both disorders are common. Methods: In this study 300 patients with 
previously confirmed diabetes or newly diagnosed diabetes according to World Health Organization criteria. The presence of hepatitis C virus    infection was tested by third 
generation ELISA kit.  Results: Out of 300 diabetics, 33 were found to be anti-HCV positive and all of them had type 2 diabetes mellitus. Serum alanine aminotransferase 
level was raised in positive cases as compared to the seronegative patients. Conclusion: The results show that there is a strong association between HCV and T2DM in the 
region as evident from significantly higher prevalence of HCV infection in diabetics as compared to the control group in the present study. 
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INTRODUCTION 
There  is  an  increasing  prevalence  of  diabetes  mellitus  (DM) 
worldwide. It has been projected that 300 million people worldwide 
will have the condition by 2015. Type-2 DM constitutes about 90% 
of the entire population with DM; hence type-2 DM will form the 
bulk of the estimated increase in prevalence by the year 2015 [1].
  
Type 2 diabetes has become more prevalent as people become 
more  obese  and  live  a  more  sedentary  lifestyle.  Risk  factors 
strongly  associated  with  type  2  diabetes  include  family  history, 
body fat distribution, age, sex, smoking, and physical activity. It 
has  also  been  suggested  that  in  addition  to  these  genetic, 
biologic,  and  demographic  factors,  HCV  infection  is  associated 
with  type  2  diabetes  [2].
  The  awareness  of  viral  hepatitis  has 
increased  over  the  past  few  decades.  Hepatitis  C  virus  (HCV) 
infection is a common cause of acute and chronic hepatitis, and 
leads  to  cirrhosis  and  hepatocellular  carcinoma.  It  is  estimated 
that nearly 150 to 200 million people have been in contact with 
HCV worldwide, and approximately 85% have chronic infection. 
Several studies from different parts of the world have found that 
13%  to  33%  of  patients  with  chronic  HCV  have  associated 
diabetes, mostly type II DM [3].
 Furthermore, most of the anti-HCV 
positive diabetic patients presented with abnormal liver function 
tests [4].  
Regarding diabetes mellitus  and  chronic HCV  infection,  there  
are  several  studies  that demonstrated  a  correlation  between  
the  two diseases. A  study performed  in  the USA on 9,822 
subjects  showed  that  the  risk  of DM  is  3.8  times higher  in 
HCV  infected  patients [5]. A  second study on 10,275 subjects 
without  DM,  followed-up  for  9  years,  showed  an    increased  
incidence of DM in  patients with  positive  anti HCV  antibodies,  
12 times higher than in general population [6]. A study performed 
in  Spain  on  176  patients  with  DM  demonstrated    that    the  
prevalence  of  anti  HCV antibodies  was  11.5%,  as  compared  
to  2.5%  in blood  donors  (6,172  tested) [7].  Prevalence  of DM  
in  the general   population of  India has gone up   from < 2%  
before 1977  to  >  12%  since  2000 [8].  In India,  the prevalence  
of HCV  ranges  from 0.3  to 4%  in  the general population [9].  
There are only a  few  studies  from  India to  document  the  
relationship  between  the  two  diseases  in question [10,11]. 
Most  studies  in  India  have  shown  a  predominance  of  HCV 
genotype III with prevalence ranging from 12% to 64% [12]. But 
effect of HCV genotype  III on  the prevalence of DM  is not widely  
known.  
Type 2  diabetes is a debilitating disease condition especially in 
people above 30 years of age and this may evolve throughout  
 
their life-span. Hence, the co-infection of type 2 diabetes and HCV 
has been established to worsen these condition, with this scenario 
it  has  become  very  necessary  for  a  screening  exercise  to 
determine the prevalence rate of HCV among diabetic patients so 
as to increase awareness of the populace and health practitioners 
on  the  dangers  of  the  co-infectious  state  of  this  virus  with 
diabetes. This study aims to evaluate the prevalence of hepatitis 
C  virus  (HCV)  infection,  clinical and  biochemical  status  of  liver 
function in Type 2 diabetes mellitus patients. 
METHODS 
The  study  was  carried  out  on  a  sample  of  300  consecutive 
persons  both  out  patients  and  inpatients  with  confirmed type  2 
diabetes at a tertiary care Hospital between January 2010 and 
December  2011.  The  exclusion  criteria  were  history  of  taking 
hepatotoxic drugs, evidence of acute clinical hepatitis and those 
who  are  HBsAg  positive.  Data  regarding  age,  sex,    and 
background characteristics of diabetes (family history of diabetes, 
duration  and  type  of  diabetes  mellitus)  and  reports  of    Serum 
bilirubin,  Alanine  aminotransferase    (ALT),  Aspartate  
aminotransferase  (AST), Alkaline  phosphatase were collected. A 
control group comprising of 3000 healthy blood donors were taken 
from  the  same  hospital  who  visited  the  blood  bank  during  the 
study period. Controls were excluded from the study if they had 
diabetes.  All the sera were tested for the presence of antibodies 
against HCV by a third generation enzyme immunoassay kit. The 
tests were performed according to   instructions with adequate 
controls.  
RESULTS 
In  this study,  out  of the  total  300  diabetic subjects studied,  33 
(11%) turned out to be anti-HCV positive. All of these 33 subjects 
(100%) had type II diabetes.  Among them, 15 (45%) subjects 
were  male  and  18  (55%)  subjects  were  female.  Regarding  the 
duration of diabetes in the anti-HCV positive subjects, 16 (48%) 
had diabetes for less than 5 years, 10 (30%) had it for 6 -10 years, 
7 (22%) had it for >11-15 years.  On observing the age groups of 
anti HCV positive diabetic patients, it was noticed that 1 subject 
(3%) was in the 20-30years range, 8 (24%) in the 31-40 years 
range, 15 (45%) were in the 41-50 years range and 9 were (28%) 
were above 50years of age.  
Considering  individuals  with  family  history  of  diabetes,  it  was 
realized  that  that  those  without  family  history  had  a  higher 
prevalence  of  60%  while  those  with  family  history  recorded  a 
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in HCV status in the type 2 diabetes patients. Those that never 
had any blood transfusion showed a higher prevalence rate of82% 
while those with an evidence of blood transfusion recorded 18%.  
Biochemical  markers  of  liver  function  were  found  to  be 
significantly  higher  in  seropositive  cases  than  seronegative 
patients. Controls were predominantly males with a median age of 
27 years, among this 0.2% (7) were positive for HCV antibodies. 
The seroprevalence was 11% in patients with T2DM as compared 
to  the  control  group  in  whom  prevalence  rate  was 
0.2%.Distribution of HCV pattern in type 2 diabetic patients was 
shown in Table 1. 
 
Table 1: Distribution of HCV pattern in type 2 diabetic patients 
 
 
Variables 
 
HCVNegative (n=267) 
 
HCV Positive (n=33) 
 
Age  
20-30  22 (8.2%)    1 (3%)   
31-40  68 (25.4%)  8 (24%) 
41-50  137 (51%)  15 (45%) 
50 above  40 (15%)  9 (28%) 
 
Gender  
Female  142 (53%)  18 (55%) 
Male  125 (47%)  15 (45%) 
 
Family history of diabetes 
No  162 (61%)  20 (60%) 
Yes  105 (39%)  11 (40%) 
 
Duration of diabetes 
1-5 years  182 (68%)  16 (48%) 
6-10 years  74 (28%)  10 (30%) 
>11 years  11 (4%)  7 (22%) 
 
History of blood transfusion 
No  259 (97%)  27 (82%) 
Yes  8 (3%)  6 (18%) 
 
Liver function tests 
ALT     
Normal  259 (97%)  6 (18%) 
Increased               8 (3%)  27 (82%) 
AST     
Normal  259 (97%)  6 (18%) 
Increased               8 (3%)  27 (82%) 
 
Serum bilirubin 
   
Normal  259 (97%)  6 (18%) 
Increased               8 (3%)  27 (82%) 
 
Alkaline Phosphatase 
   
Normal  259 (97%)  6 (18%) 
Increased               8 (3%)  27 (82%) 
 
 
DISCUSSION 
The association of diabetes mellitus with chronic liver disease has 
been  recognized  many  years  ago.  Russian  endocrinologists 
reported  abnormalities  of  glucose  tolerance  in  28%  of  patients 
with chronic liver disease in 1977 [13]. The increased frequency 
has been supported in many other studies. Simo et al, in 1996 
found  that  HCV  infection  in  diabetic  patients  was  4.39  times 
higher compared to the control group [14]. Similarly, a study in 
Pakistan reported a higher frequency of HCV infection, particularly 
genotype 2a, among diabetic patients [15]. The prevalence rate of 
11% recorded in this study is in agreement with the work of Simo 
et al 
 who also recorded 11.5% against 2.5% when prevalence of  
HCV  infection  was  checked  among  diabetic  patients  and  blood 
donors respectively.  
In this study the occurrence of HCV among type 2 diabetes was 
higher in subjects aged 41–50 years, this agrees with the findings 
of Mehta et. al. 
 who showed that individuals of >40 years are 
more prone to type 2 diabetes. Equally in this study, subjects less 
than  33  years  of  age  recorded  a  very  low  prevalence  of  HCV 
infection, which also agrees with the report of Mehta et al. that 
type 2 diabetes, occurs more often with HCV infection in those 
older than 40 years of age. It was also observed in some previous 
studies, that older patients were more likely to have HCV infection 
as compared to those in the younger age groups [16].
  The high 
seropositivity recorded in older group may be because of more 
parenteral exposures as compared to younger people and thus 
greater chances of transmission of infection. We also observed 
that majority  of the seropositive patients had diabetes of less than 
5  years  duration.  This  shows  that  the  chronicity  of  diabetes 
mellitus is not a predisposing factor for HCV infection.  
A significant difference was observed in participants with a family 
history of diabetes mellitus and those without. Interestingly, this 
coincides with the work of Muller et al  and Del et al  Where it was 
found  that  increased  occurrence  was  associated  with  family 
history of diabetes mellitus and this variable may be one of the 
reasons  of  higher  frequency  of  diabetes  mellitus  type  2  in  this 
group  of  patients  [17,18].  We  also  observed  elevated  liver 
enzymes;  especially  ALT  has  a  direct  relationship  with 
seropositivity in the diabetic population, showing the relevance of 
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more  than  20%  of  diabetes  patients  with  consistently  elevated 
serum aminotransferases had evidence of HCV infection [19]. 
CONCLUSION 
There is a significant association between hepatitis C virus and 
type  2  diabetes  from  the  findings  of  this  research  work  which 
might be on the increase, this calls for an urgent need to educate 
the  populace  on  the  dangers  of  the  co-infection  of  HCV  and 
diabetes it's also vital for all health care practioners to come to 
terms with the early diagnosis and Management of this condition 
in affected patients. The presence of raised serum SGPT/ Alanine 
Amino Transaminase (ALT) levels in diabetic subjects should be 
considered  as  an indication for  further  investigations  of chronic 
liver disease and especially HCV infection. Further investigation 
into  the  association  of  the  two  conditions  is  needed  and  may 
elucidate  the  temporal  relationship  and  improved  management 
strategies. 
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